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Gregory L. Moneta, MD, Section EditorFemoral vs Jugular Venous Catheterization and Risk of Nosocomial
Events in Adults Requiring Acute Renal Replacement Therapy: A
Randomized Controlled Trial
Parienti J-J, ThirionM,Megarbane B, et al; Members of the Cathedia Study
Group. JAMA 2008;299:2413-22.
Conclusions: Jugular venous catheterization vs femoral venous cath-
eterization for initial acute renal replacement therapy may have a higher risk
of hematoma and does not reduce the risk of infectious complications except
perhaps in adults with high body mass index (BMI).
Summary: It is widely believed infectious complications associated
with acute renal replacement therapy are reduced with jugular access vs
femoral access for short-term dialysis. In this study the authors sought to
determine whether jugular catheterization actually decreases the risk of
nosocomial complications compared with femoral catheterization. This was
a randomized, concealed, multicenter, evaluator-blinded, parallel group
trial with 750 patients from three general hospitals in France and nine
tertiary care university medical centers conducted between May 2004
and May 2007. Patients were severely ill and bed-bound with a BMI of
45 and required a first catheter insertion for renal replacement therapy.
The individuals who did the jugular or femoral vein catheterizations were
experienced in both types of replacement sites. The main outcome
measures included rates of infectious complications (catheter coloniza-
tion on removal [primary end point] and catheter related bloodstream
infection).
Patient characteristics and duration of catheterization were similar in
both groups. Hematomas occurred in 13 of 366 patients (3.6%) in the
jugular group compared with four of 370 patients (1.1%) in the femoral
group (P  .03). The risk of catheter colonization at removal of the access
catheter was not significantly different between the jugular and femoral
groups (35.7 vs 40.8 for 1000 catheter-days; hazard ratio [HR], 0.85; 95%
confidence interval [CI], 0.62-1.16; P  .31).
A prespecified subgroup analysis demonstrated significant qualitative
heterogeneity by BMI (P  .001 for the interaction term). There was a
significant increased risk of catheter colonization with jugular catheteriza-
tion vs femoral catheterization (45.4 vs 23.7 per 1000 catheter-days; HR,
2.10; 95% CI, 1.13-3.91; P  .17) and the lowest tercile of BMI (24.2)
Jugular catheterization significantly decreased the incidence of catheter
colonization in the highest tercile of BMI (24.5 vs 50.9 for 1000 catheter-
days; HR, 0.4; 95% CI, 0.23-0.69, P .001). Catheter-related bloodstream
infection was similar in both groups (2.3 vs 1.5 per 1000 catheter-days,
respectively; P  .42).
Comment:The authors’ data are inconsistent with the widely accepted
belief of avoiding femoral catheterization to prevent risk of catheter-related
infection in patients undergoing acute renal replacement therapy, the excep-
tion being those individuals with a significantly increased BMI. However,
this was a large, multicenter randomized trial and the data therefore must be
taken seriously. Except for the patients with elevated BMI, there appears to
be no particular advantage, and perhaps a disadvantage in terms of hema-
toma formation, of using the jugular site vs the femoral site for acute renal
replacement therapy.
Gene Expression Analysis of a Porcine Native Abdominal Aortic An-
eurysm Model
Sadek M, Hynecek RL, Goldenberg S, et al. Surgery 2008;144:252-8.
Conclusion: A porcine model of gene expression during development
of an abdominal aortic aneurysm (AAA) reflects gene expressions found in
human studies and in rodent models of AAA.
Summary: The authors sought to characterize gene expression pat-
terns during development of AAAs in the native pig aorta. Aneurysms were
produced in Yorkshire swine. An infrarenal aortic balloon was dilated and
infused with a solution of type I collagenase/pancreatic porcine elastase.
Control and aneurysmal aortic samples were obtained at 1, 2, and 4 weeks
after aneurysm induction. From these samples RNA was isolated and con-
verted to biotin-modified antisense RNA. This was then hybridized to
porcine genome arrays.
Extracellular matrix remodeling genes that were upregulated in aneu-
rysmal vs control tissue included matrix metalloproteinase-1, -2, -3, and -9,
cathepsin-D, -H, -K, and -S, tissue inhibitor metalloproteinase-1, and
collagen I- 1 chain (P .01). Elastin was temporarily down-regulated (P
.01). Up-regulated inflammatory genes included intercellular adhesion
molecule-2, tumor necrosis factor-. and interleukin (IL) 1 and IL-10,
chemokine receptor-4, and tissue plasminogen activator (P  .01). Athero-
sclerosis and cancer genes were up-regulated. These included apolipoprotein
1352E, acyl-CoA binding protein, friend leukemia virus integration-1, and E26
transformation-specific sequence (P  .01).
Comment: Relevant animal models are obviously important to the
investigation of human disease. There are rodent models for AAA where
gene expressions more or less mimic those of the human condition. Rodent
models, however, are too small to test endovascular devices. The authors of
the current study have demonstrated broad similarities between expressions
that exist in a porcine model of AAA, the human condition, and previously
described rodent models. Although the similarities are not exact, and there
may be differences in temporal expressions of RNA, it is likely this model will
prove useful in investigations of AAA.
Effect of PCI on Quality of Life in Patients with Stable Coronary
Disease
Weintraub WS, Spertus JA, Kolm P, et al; the COURAGE Trial Research
Group. N Engl J Med 2008;359:677-87.
Conclusions: In patients with stable angina, those treated with percu-
taneous coronary intervention (PCI) and optimal medical management, and
those treated with optimal medical management both havemarked improve-
ment in quality of life during follow-up. Initially, those treated with PCI
have a small incremental benefit vs those treated with medical management
alone. After 36 months there is no difference in health status between the
two groups.
Summary: Up to one-third of PCIs have been performed in patients
with stable angina. This is despite the fact that patients with chronic coronary
disease do not have a reduction in major cardiovascular events when treated
with PCI vs best medical management. The argument has been made that
PCI reduces angina symptoms more effectively than best medical manage-
ment and therefore improves quality of life. In this study the authors
analyzed quality of life data to determine whether quality of life was
enhanced by a strategy of PCI in patients with chronic coronary artery
disease.
This was a randomized, not blinded, multicenter trial that took place in
50 centers in the United States and Canada, with sponsorship and oversight
of the trial provided by the Department of Veterans’ Affairs Cooperative
Studies Program. The study randomly assigned 2287 patients with stable
coronary artery disease to optimum medical therapy alone, or PCI plus
optimal medical therapy. Angina-specific health status was assessed using the
Seattle Angina Questionnaire. Scores ranged from 0 to 100, with highest
scores indicating better health status. The RAND 36-Item Health Survey
was used to assess overall physical and mental function.
Upon entering the trial, 22% of the patients were free of angina. After
3 months, 42% in the medical therapy group alone and 53% of the PCI
patients were angina-free (P  .001). The mean  SD Seattle Angina
Questionnaire scores at baseline were 66 25 for physical limitations, 54
32 for angina stability, 69 26 for angina frequency, 87 16 for treatment
satisfaction, and 51 for quality of life. By 3 months these baseline scores
increased more in the PCI group compared with the medical therapy group:
76 24 vs 72 23 for physical limitation (P .004), 77 28 vs 73 27
for anginal stability (P .002), 85 22 vs 80 23 for angina frequency (P
.001), 92 12 vs 90 14 for treatment satisfaction (P .001), and 73
22 vs 68 23 for quality of life (P .001). Overall, incremental benefit for
PCI was present for 6 to 24 months, and patients with more severe angina
had greater benefit from PCI. Similar results occurred in the PCI group in
some, but not all, RAND-36 domains. At 36months there was no significant
difference in health status between the two groups.
Comment: This was not a “head to head” trial of medical therapy vs
PCI. The trial, in fact, compared a strategy of initial PCI plus optimal
medical therapy vs optical medical therapy alone initially. Eventually 21% of
the patients in the medical therapy alone group crossed over and received
PCI. Therefore, what this trial tells us is that in patients with stable coronary
disease, initial management should be optimal medical therapy, and if this is
ineffective, patients should then be treated with coronary intervention.
Endovascular Stenting for Traumatic Aortic Injury: An Emerging New
Standard of Care
Moainie SL, Neschis DG, Gammie JS. Ann Thorac Surg 2008;85:1625-30.
Conclusion: Aortic endografting is a safe and efficient treatment for
traumatic thoracic aorta injury secondary to blunt trauma.
Summary:The authors present a 2-year series of 26 patients with blunt
thoracic aortic injury who were treated with aortic endografts. The authors
retrospectively compare these patients with the prior 26 patients presenting
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trauma severity score was calculated for each patient to predict mortality
based on severity of injury and degree of physiologic derangement on
presentation.
Nine patients were treated with the Gore TAG stent graft (W. L. Gore
and Associates, Flagstaff, Ariz), and 17 underwent repair using proximal
extension cuffs from the Excluder AAA endoprosthesis. Excluder devices
were used in patients with aortic diameters 26 cm. Patients treated with
conventional open repair had left thoracotomy with single-lung ventilation
and left-heart bypass. Two patients treated with endografting required
additional procedures, one for type I endoleak and one for delayed graft
collapse, with the latter requiring open operation and graft retrieval and
interposition graft placement. Six patients underwent coverage of the left
subclavian artery during endograft placement, with no adverse sequelae.
Patients treated with endografting had significantly shorter lengths of
stay, less intraoperative blood loss, decreased 24 hour blood transfusion
requirements, and a lower incidence of postoperative tracheostomies com-
pared with patients undergoing open repair of thoracic aortic injuries. There
was no difference in survival between the two groups.
Comment: Despite off-label use and the occasional dramatic compli-
cation of endograft collapse, thoracic stent grafting has rapidly emerged as
standard of care for patients with blunt thoracic aortic trauma. Unlike
patients generally treated for degenerative aneurysms, patients with blunt
thoracic aortic trauma are comparatively much younger. Their aortas will
elongate and dilate as they age. The fate of these grafts over the very long
termwill therefore be very interesting to observe. Given the demographics of
much of the trauma population, I wonder how many of these patients are
actually returning for follow-up examinations? Follow-up in this study was
rather limited. No data were presented beyond hospital discharge.
Ovarian Vein Incompetence: A Potential Cause of Chronic Pelvic Pain
in Women
TropeanoG,Di Stasi C, Amoroso S, et al. Eur J Obstet Gynecol Reprod Biol
2008;139:215-21.
Conclusion: Ovarian vein incompetence is a cause of chronic pelvic
pain in women and responds to ovarian vein sclerotherapy.
Summary: For many years investigators have suggested pelvic varices
can be responsible for otherwise unexplained pelvic pain. Venographic
studies have demonstrated dilation of major pelvic veins with congestion of
the ovarian plexus and broad ligaments in a high percentage of women with
chronic pelvic pain and normal laparoscopy. It appears retrograde flow in
incompetent ovarian veins may be the primary mechanism for dilation of
pelvic veins and congestion of surrounding tissues leading to chronic pelvic
pain. The clinical utility of ovarian vein occlusion and the treatment of such
women are controversial.
The authors evaluated 22 women with laparoscopy aged 19-50 years
who had chronic pelvic pain and no recognized pelvic pathology. All did
have evidence of reflux and dilated pelvic veins on transvaginal color Doppler
ultrasound and subsequently underwent retrograde ovarian vein venography
and sclerotherapy of incompetent ovarian veins. Outcomes were assessed by
a symptom questionnaire and visual analog pain scales at 3, 6, and 12
months. Serial ultrasound examinations were used to evaluate changes in
pelvic circulation after sclerotherapy.
Venography showed 20 of the 22 women had incompetent ovarian
veins, and they subsequently received sclerotherapy, which was not associ-
ated with immediate or late complications. Symptom improvement of
varying magnitude was observed in 85% of the 20 treated women at a mean
follow-up of 12 months. Marked or complete relief occurred in 15 patients
and mild to moderate relief in two patients, with three women (15%) having
no improvement in symptoms. Median visual analog pain scales at 3, 6, and
12months were significantly lower than at baseline: 2.0, 2.5, and 3.0 at 3, 6,
and 12 months vs 8.0 at baseline (P  .001). Follow-up ultrasound
examinations demonstrated recurrence of venous reflux in three patients at 3
months.
Comment: All the women in this study underwent laparoscopy. In
fewer than half were pelvic varices detected by laparoscopy, indicating the
absence of pelvic varicosities at laparoscopy does not rule out the diagnosis.
Ovarian vein reflux as a cause of so-called pelvic congestion syndrome will
remain controversial. The data do suggest, in patients who have had a
thorough history, clinical evaluation, and negative results on standard diag-
nostic tests, that ovarian venography should be considered with the idea of
possibly treating underlying ovarian vein reflux.
Preoperative Shower Revisited: Can High Topical Antiseptic Levels be
Achieved on the Skin Surface Before Surgical Admission?
Edmiston CE Jr, Krepel CJ, Seabrooke GR, et al. J Am Coll Surg 2008;207:
233-9.Conclusion: It is possible to achieve effective decolonization of the
skin before hospital admission in surgical patients.Summary: A recent controversial review from the Cochrane Collabo-
ration suggested evidenced-based data do not support the use of preopera-
tive baths or showers with aseptic agents to reduce surgical site infections in
patients undergoing a surgical procedure (Webster J, Osborne S. Preopera-
tive bathing or showering with skin antiseptics to prevent surgical site
infection. Cochrane Database Syst Rev 2007:CD 004985).
In this study, the authors sought to determine the effectiveness of
chlorhexidine gluconate (CHG) skin concentrations after preoperative
showering/skin cleansing. Two strategies were used to administer the CHG.
Patients used either (A) 4% CHG soap or (B) 2% CHG-impregnated
polyester cloths. There were three shower group strategies used, with 20
subjects per group; each group was divided into 4% CHG soap or 2%
CHG-impregnated polyester cloths. Group 1 A/B patients had evening
showering or skin cleansing, group 2 A/B patients had morning showering
or skin cleansing, and group 3 A/B patients had evening and morning
showering or skin cleansing. After showering or skin cleansing, CHG skin
surface concentrations were determined at five separate skin sites. CHG
concentrations were then compared with CHG minimal inhibitory concen-
trations that inhibited 90% (MIC90) of staphylococcal isolates.
The CHG MIC90 for 61 skin isolates was 4.8 parts per million (ppm).
CHG skin concentrations in the various groups were as follows: group 1A,
17.2 to 31.6 ppm; group 1B, 361.5 to 589.5 ppm (P  .001); group 2A,
51.6 to 119.6 ppm; group 2B, 848.1 to 1049.6 ppm (P .0001); group 3A,
101.4 to 149.4 ppm; and group 3B, 1484.6 to 2031.3 ppm. In subjects
treated with strategy A, effective CHG levels were not detected at selected
sites in 35% of subjects in group 1A, in 15% of subjects in group 2A, and in
25% of subjects in group 3A. There were no subjects who used the 2% CHG
impregnated polyester cloth (strategy B) with skin sites without detectable
CHG levels.
Comment: The Cochrane Collaborative appropriately pointed out the
gap between preoperative skin antisepsis and evidence-based outcomes to
reduce surgical site infection. We still do not know the effect of a carefully
administered preoperative program of skin decolonization on actual reduc-
tion in surgical site infection. As in this study, the surrogate end point of
CHG concentrations does not reflect the clinical end point of surgical site
infection. In addition, none of the volunteers in this study had a body mass
index 40. Comorbidities such as diabetes, renal failure, and nutritional
status that may affect surgical site infection were not assessed. Nevertheless,
it does appear possible to achieve CHG concentrations in the skin that
considerably exceed the MIC90 for staphylococcal isolates. Therefore, al-
though the data are not perfect, there seems little downside in the use of
preoperative antiseptic shower or skin cleansing and it appears that a 2%
CHG-impregnated polyester cloth is superior to 4% CHG soap in achieving
effective MICs on the skin.
Renal Stenting for Incidentally Discovered Renal Artery Stenosis: Is
There Any Outcome Benefit?
Suliman A, Imhoff L, Greenberg JI, et al. Ann Vasc Surg 2008;22:525-33.
Conclusion: Stenting of incidentally discovered renal artery stenoses at
the time of an angiogram performed for another indicated procedure results
in minimal benefit compared with medical management alone.
Summary: Significant renal artery stenosis is frequently encountered at
the time of angiography performed for other forms of arterial disease. The
authors performed a retrospective medical record review of patients under-
going renal arteriography during 4 years. They used catheterization reports
to identify patient diagnosed with high-grade renal artery stenosis (70%).
Patients treated with renal artery angioplasty were identified, and baseline
and postprocedural blood pressure, glomerular filtration rate, serum creati-
nine, and antihypertensive medication regimens were compared after 12
months of follow-up.
During the 4-year period, 124 patients underwent renal arteriography
with 78 (63%) diagnosed with high-grade renal artery stenosis. Renal artery
stents were placed in 58 patients (74%). When compared with the patients
with high-grade renal artery stenosis who received no intervention, the
patients with renal artery stents had similar baseline characteristics with the
exception of lower diastolic blood pressure (74  11.2 vs 80  14.2 mm
Hg, P  .04) and a higher proportion of increased lipids (78% vs 55%, P 
.05). Follow-up was available in 58 of the renal artery stented patients (66%).
Postprocedural variables in patients with renal artery stents with 12-month
follow-up indicated there was reduction in systolic blood pressure (153 
20.8 vs 136  27.2, P  .01) and mean arterial pressure (103  11.2 vs
95  14 mm Hg, P  .04). Significant reductions in systolic mean arterial
and diastolic blood pressure were, however, only noted in the patients who
also had an increase in the number of antihypertensive medications. There
were no differences in renal insufficiency detected.
Comment: This is a retrospective study with incomplete data. Never-
theless, it is certainly not a testimonial to the efficacy of renal artery stents in
patients with unsuspected renal artery stenosis. The only parameter that
improved in the stented patients was blood pressure, and that only improved
if there was an increase in antihypertensive medications. The data do not
support routine practice of renal angioplasty and stenting for incidentally
